Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 4/20 | 0.84 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.84 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.84 |
| ▸ | PI4KA | P42356 | 1/20 | 0.72 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.72 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.72 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.72 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.71 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.69 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.69 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.69 |
| ▸ | LDHA | P00338 | 1/20 | 0.69 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.69 |
| ▸ | FBP1 | P09467 | 1/20 | 0.69 |
| ▸ | SRC | P12931 | 1/20 | 0.69 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.69 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.69 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.69 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.69 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26361537 | 1.00 | P2RX3 (0.84) | P2RX3P2RX1P2RX4PI4KAPI4K2B | |
| SCHEMBL22402648 | 1.00 | P2RX3 (0.84) | P2RX3P2RX1P2RX4PI4KAPI4K2B | |
| SCHEMBL23922240 | 0.93 | P2RX3 (0.97) | P2RX3P2RX1P2RX4PI4KAPI4K2B | |
| SCHEMBL14414863 | 0.93 | P2RX3 (0.97) | P2RX3P2RX1P2RX4PI4KAPI4K2B | |
| SCHEMBL3781395 | 0.91 | P2RX3 (0.76) | P2RX3P2RX1P2RX4PI4KAPI4K2B | |
| SCHEMBL24145102 | 0.89 | P2RX3 (0.87) | P2RX3P2RX1P2RX4PI4KAPI4K2B | |
| SCHEMBL27480257 | 0.87 | PI4KA (0.76) | P2RX3P2RX1P2RX4PI4KAPI4K2B | |
| SCHEMBL22402624 | 0.87 | P2RX3 (0.70) | P2RX3P2RX1P2RX4PI4KAPI4K2B | |
| SCHEMBL23922243 | 0.87 | P2RX3 (0.70) | P2RX3P2RX1P2RX4PI4KAPI4K2B | |
| SCHEMBL26361549 | 0.87 | P2RX3 (0.70) | P2RX3P2RX1P2RX4PI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124511-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | TIANJIN HONGKE BAISHI QIXIN VENTURE CAPITAL PARTNERSHIP (LIMITED PARTNERSHIP) (CN) | 2024-04-18 | — | — | US | disclosed |
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-11773131-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| US-20220017560-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | WUXI PHARMATECH HEALTHCARE FUND I L.P. (CN) | 2022-01-20 | — | — | US | disclosed |
| US-20210403501-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | SHANGHAI XINQI WU FILM AND TELEVISION INVESTMENT CO., LTD. (CN) | 2021-12-30 | — | — | US | disclosed |
| US-11186606-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2021-11-30 | — | — | US | disclosed |
| US-11149051-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2021-10-19 | — | — | US | disclosed |
| US-20200283468-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | LUMINEX INTERNATIONAL (CN) | 2020-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017560-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | PHKA1, PHKA2, PRKCA | P2RX3 1233/4885P2RX1 885/4885P2RX4 2015/4885 |
| US-11186606-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | P2RX3 1233/4885P2RX1 885/4885P2RX4 2015/4885 |
| US-20200283468-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | PHKA1, PHKA2, PRKCA | P2RX3 1233/4885P2RX1 885/4885P2RX4 2015/4885 |
| US-11149051-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | P2RX3 1233/4885P2RX1 885/4885P2RX4 2015/4885 |
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | P2RX3 1233/4885P2RX1 885/4885P2RX4 2015/4885 |
| US-20240124511-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | PHKA1, PHKA2, PRKCA | P2RX3 1233/4885P2RX1 885/4885P2RX4 2015/4885 |
| US-11773131-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | P2RX3 1233/4885P2RX1 885/4885P2RX4 2015/4885 |
| US-20210403501-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | PHKA1, PHKA2, PRKCA | P2RX3 1233/4885P2RX1 885/4885P2RX4 2015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.